Fin Dec Wealth Services, Inc. Cardiff Oncology, Inc. Transaction History
Fin Dec Wealth Services, Inc.
- $172 Billion
- Q3 2024
A detailed history of Fin Dec Wealth Services, Inc. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Fin Dec Wealth Services, Inc. holds 16,000 shares of CRDF stock, worth $40,160. This represents 0.02% of its overall portfolio holdings.
Number of Shares
16,000
Previous 16,000
-0.0%
Holding current value
$40,160
Previous $35.5 Million
20.27%
% of portfolio
0.02%
Previous 0.02%
Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
90Shares Held
12.3MCall Options Held
813KPut Options Held
91.1K-
Black Rock Inc. New York, NY2.63MShares$6.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$5.45 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$2.33 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$2.09 Million0.0% of portfolio
-
Mai Capital Management663KShares$1.67 Million0.02% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $109M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...